Real-world results confirm benefit of antigen therapy for prostate cancer
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, consistent with outcomes from the VISION trial. An analysis of outcomes from a French early-access program, the largest real-world cohort of patients studied to date, confirms the benefit-risk…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Mental health disparities persist for LGBTQ+ college students nationwide, largest study of its kind finds
United Kingdom
-
ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer
United Kingdom
-
Six-gene scoring system could help predict leukemia survival
United Kingdom
-
How cancers evade chemotherapy by entering a 'zombie-like state'
United Kingdom
-
Cancer cells' own carbon monoxide fuels anticancer drug production in lab tests
United Kingdom
-
Procedure standard/procedure guideline for ventilation–perfusion pulmonary scintigraphy published
United Kingdom
-
Maternal stress alters placental pathways affecting fetal brain development
United Kingdom
-
FDA approves hepatitis B shot that may let some patients stop all treatment
United Kingdom